About SynDevRx

Intellectual Property

Our innovations and drug development approach are based on precedent.  Decades of work on molecular targets, drug SAR (structure-activity relationship), polymer conjugation theory and clinical experience have informed our drug development program.

Using 30+ years of accumulated clinical knowledge, we have developed best-in-class fumagillol-polymer conjugates. They combine highly active, novel fumagillol derivatives conjugated to a stable, bio-compatible polymer.

SynDevRx has developed proprietary drug conjugation chemistries (composition of matter) that increase the activity of small molecule drugs while improving their safety profile and physical attributes. 

 


NB: SynDevRx is not affiliated with Children's Hospital Boston.